Posted by Michael Wonder on 21 Jan 2019
Europe closer to biosimilar rule change, despite fierce resistance from pharma
18 January 2019 - EFPIA says it weakens IP commitment - supporters say it will boost exports.
The European Union is a step closer to introducing new rules aimed at boosting exports of generics and biosimilars from the region – despite dogged opposition from the pharmaceutical industry.
Europe’s pharma industry body EFPIA says the changes send a signal that Europe is “weakening its commitment to IP incentives and innovation”. However the generics and biosimilar sector says this is scaremongering, and the move will in fact boost its exports and create jobs, without doing any harm to innovation-based pharma.
